Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)

  • Genescà, Eulàlia|||0000-0002-5657-4842
  • Morgades, Mireia|||0000-0003-0295-2534
  • González Gil, Celia|||0000-0002-7582-1482
  • Fuster-Tormo, Francisco|||0000-0002-1220-6183
  • Haferlach, Claudia
  • Meggendorfer, Manja
  • Montesinos, Pau|||0000-0002-3275-5593
  • Barba, Pere|||0000-0001-7076-7969
  • Gil, Cristina
  • Coll, Rosa|||0000-0003-0560-1254
  • Moreno, Maria José
  • Martínez-Carballeira, Daniel|||0000-0003-4840-7822
  • García Cadenas, Irene|||0000-0002-2994-9055
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • González Campos, José
  • Díaz-Beyá, Marina|||0000-0001-9624-2597
  • Mercadal, Santiago|||0000-0003-4741-7885
  • Artola, Maria Teresa
  • Cladera, Antonia
  • Tormo, Mar|||0000-0001-9622-1649
  • Bermúdez, Arancha
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Amigo, María-Luz|||0000-0002-3356-9290
  • Monsalvo, Silvia
  • Novo, Andrés
  • Cervera, Marta
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Ciudad Pizarro, Juana
  • Cervera, José|||0000-0001-8252-1106
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • Granada, Isabel|||0000-0002-4275-0104
  • Haferlach, T.|||0000-0003-0196-2837
  • Orfao, Alberto|||0000-0002-0007-7230
  • Sole, F.|||0000-0002-3251-2161
  • Ribera, Jose-Maria|||0000-0003-1042-6024
The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. Complex karyotype defined by the presence of ≥3 cytogenetic alterations identified T-ALL patients with poor prognosis in this study. Karyotypes with ≥3 abnormalities accounted for 16 % (22/139) of all evaluable karyotypes, corresponding to the largest poor prognosis cytogenetic subgroup of T-ALL identified so far. Patients carrying karyotypes with ≥3 cytogenetic alterations showed a significantly inferior response to therapy, and a poor outcome in terms of event-free survival (EFS), overall survival (OS) and cumulative incidence of relapse (CIR), independently of other baseline characteristics and the end-induction minimal residual disease (MRD) level. Additional molecular analyses of patients carrying ≥3 cytogenetic alterations showed a unique molecular profile that could contribute to understand the underlying molecular mechanisms of resistance and to evaluate novel targeted therapies (e.g. IL7R directed) with potential impact on outcome of adult T-ALL patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols

  • Barba, Pere|||0000-0001-7076-7969
  • Morgades, Mireia|||0000-0003-0295-2534
  • Montesinos, Pau|||0000-0002-3275-5593
  • González Campos, José
  • Torrent Catarineu, Anna|||0000-0002-3727-5716
  • Gil, Cristina
  • Bernal, Teresa|||0000-0002-2338-513X
  • Tormo, Mar|||0000-0001-9622-1649
  • Mercadal, Santiago|||0000-0003-4741-7885
  • Novoa, Sandra
  • García Cadenas, Irene|||0000-0002-2994-9055
  • Queipo de Llano, M. Paz
  • Cervera, Marta
  • Coll, Rosa|||0000-0003-0560-1254
  • Bermúdez, Arancha
  • Amigo, María-Luz|||0000-0002-3356-9290
  • Monsalvo, Silvia
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
  • Garcia-Boyero, Raimundo
  • Novo, Andres
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • Cladera, Antonia
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Serrano, Josefina
  • Artola, Maria Teresa
  • Soria, Beatriz
  • Abella Monreal, Eugenia|||0000-0001-9605-8458
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Bergua Burgues, Juan Miguel|||0000-0001-8229-1208
  • Herrera, Pilar|||0000-0002-4118-7110
  • Barrios, Daniel
  • Ribera, Jose-Maria|||0000-0003-1042-6024
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

  • Kwon, Mi|||0000-0002-3855-7774
  • Iacoboni, Gloria|||0000-0003-0805-9288
  • Reguera-Ortega, Juan Luis
  • López Corral, Lucia|||0000-0003-1908-5596
  • Morales, Rafael Hernani
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • Guerreiro, Manuel
  • Caballero, Ana Carolina|||0000-0002-4950-5259
  • Domínguez, María Luisa Guerra
  • Sánchez Pina, José María|||0000-0002-9181-0900
  • Mussetti, Alberto|||0000-0002-4088-036X
  • Sancho, Juan-Manuel|||0000-0001-7168-6538
  • Bastos, Mariana|||0000-0002-9431-4646
  • Catalá, Eva|||0000-0003-3478-9110
  • Delgado, Javier
  • Henriquez, Hugo Luzardo
  • Sanz, Jaime|||0000-0001-6934-4619
  • Calbacho, Maria|||0000-0001-8106-4863
  • Bailén, Rebeca|||0000-0003-2838-1776
  • Carpio Segura, Cecilia del Carmen|||0000-0001-9346-0134
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Sureda, Anna|||0000-0002-1238-6970
  • Briones Meijide, Javier|||0000-0003-2750-3735
  • Hernandez-Boluda, Juan Carlos|||0000-0002-4289-3113
  • Martínez Cibrián, Núria|||0000-0002-8688-1202
  • Martin, Jose Luis Diez
  • Martín, Alejandro
  • Barba, Pere|||0000-0001-7076-7969
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. Data from consecutive patients with R/R LBCL who underwent apheresis for axi-cel or tisa-cel were retrospectively collected from 12 Spanish centers. A total of 307 patients underwent apheresis for axi-cel (n=152) and tisa-cel (n=155) from November 2018 to August 2021, of which 261 (85%) received a CAR T infusion (88% and 82%, respectively). Median time from apheresis to infusion was 41 days for axi-cel and 52 days for tisa-cel (P =0.006). None of the baseline characteristics were significantly different between both cohorts. Both cytokine release syndrome and neurologic events (NE) were more frequent in the axi-cel group (88% vs. 73%, P =0.003, and 42% vs. 16%, P <0.001, respectively). Infections in the first 6 months post-infusion were also more common in patients treated with axi-cel (38% vs. 25%, P =0.033). Non-relapse mortality was not significantly different between the axi-cel and tisa-cel groups (7% and 4%, respectively, P =0.298). With a median follow-up of 9.2 months, median PFS and OS were 5.9 and 3 months, and 13.9 and 11.2 months for axi-cel and tisa-cel, respectively. The 12-month PFS and OS for axi-cel and tisa-cel were 41% and 33% (P =0.195), 51% and 47% (P =0.191), respectively. Factors associated with lower OS in the multivariate analysis were increased lactate dehydrogenase, ECOG ≥2 and progressive disease before lympho-depletion. Safety and efficacy results in our real-world experience were comparable with those reported in the pivotal trials. Patients treated with axi-cel experienced more toxicity but similar non-relapse mortality compared with those receiving tisa-cel. Efficacy was not significantly different between both products.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation

  • Guglieri-Lopez, Beatriz
  • Perez-Pitarch, Alejandro
  • García Cadenas, Irene|||0000-0002-2994-9055
  • Gimenez, Estela
  • Barba, Pere|||0000-0001-7076-7969
  • Rabella, Núria|||0000-0002-3409-0468
  • Hernandez-Boluda, Juan Carlos|||0000-0002-4289-3113
  • Fox, Maria Laura|||0000-0002-0062-6607
  • Valcárcel, David|||0000-0002-8747-078X
  • Esquirol, Albert|||0000-0002-6062-5980
  • Ferriols-Lisart, Rafael
  • Sierra, Jorge|||0000-0002-7966-0356
  • Solano, Carlos|||0000-0003-3702-0817
  • Navarro, David
  • Martino Bofarull, Rodrigo|||0000-0001-5143-4042
  • Piñana, José Luis|||0000-0001-8533-2562
The current study evaluates the clinical effect of sirolimus exposure on the occurrence of cytomegalovirus (CMV)DNAemia necessitating preemptive antiviral therapy. A total of 167 consecutive recipients of reduced-intensity conditioning (RIC)allogeneic hematopoietic stem cell transplantation (allo-HSCT)who received sirolimus- and tacrolimus-based graft-versus-host disease (GVHD)prophylaxis and whose CMV serostatus was positive for donors and/or recipients were included in this multicenter retrospective study. A parametric model with consecutive sirolimus blood levels describing the time to CMV DNAemia-RAT was developed using NONMEM version 7.4. Overall, 122 of 167 patients (73%)were allografted from an unrelated donor, and the donor CMV-serostatus was negative in 51 cases (31%). Fifty-six recipients (34%)developed CMV DNAemia necessitating preemptive therapy, with a cumulative incidence of 36% at a median follow-up of 25 months. Time to CMV DNAemia necessitating preemptive therapy was best described using a Gompertz function. CMV DNAemia necessitating preemptive therapy-predicting factors were antithymocyte globulin-based conditioning regimen (hazard ratio [HR], 2.2; 95% confidence interval [CI], 1.1 to 4.1; P <.01)and sirolimus concentration (HR,.94; 95% CI,.87 to.99; P <.01). The risk of CMV DNAemia-RAT decreased by 6% for each 1 ng/mL increase in sirolimus trough concentration. In conclusion, we provide evidence on the association between sirolimus blood concentration and incidence of CMV DNAemia necessitating preemptive therapy in allo-HSCT recipients. Moreover, this study presents the first predictive model describing the time to CMV DNAemia necessitating preemptive antiviral therapy as a function of sirolimus drug concentration.